Hypertension

  • Pheochromocytoma: current diagnosis and management

    Donald G. Vidt, MD, Alan Bakst, PharmD, William M. Manger, MD, PhD and Ray W. Gifford Jr, MD
    • Cleveland Clinic Journal of Medicine September 1993, 60 (5) 365-378;

    • In patients with paroxysmal or sustained hypertension, especially if symptoms are present, pheochromocytoma should be suspected.

  • The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: insights and highlights from the chairman

    Donald G. Vidt, MD, Alan Bakst, PharmD and Ray W. Gifford Jr, MD
    • Cleveland Clinic Journal of Medicine July 1993, 60 (4) 273-277;

    • Highlights include the new classification schema and recommendations on the use of labetalol.

  • The role of multiple risk factors in cardiovascular morbidity and mortality

    Ray W. Gifford Jr, MD
    • Cleveland Clinic Journal of Medicine May 1993, 60 (3) 211-218;
    • BACKGROUND

      Cardiovascular disease remains the leading cause of death in the United States.

  • Current hypertension management: separating fact from fiction

    Donald G. Vidt, MD, Alan Bakst, PHARMD and Marvin Moser, MD
    • Cleveland Clinic Journal of Medicine January 1993, 60 (1) 27-37;

    • Speculations that have led many physicians to abandon the use of diuretics have not proven to be of clinical relevance in most instances.

  • Primary pulmonary hypertension, then and now: 28 years of experience

    Benjamin D. Robalino, MD and Douglas S. Moodie, MD, MS
    • Cleveland Clinic Journal of Medicine July 1992, 59 (4) 411-417;

    • Patients with PPH are presenting at earlier stages of the disease, have fewer complications during cardiac catheterization, and probably survive longer after diagnosis than patients seen several decades ago.

  • Adrenergic agents: clinical trials and experiences

    Donald G. Vidt, MD, Alan Bakst, PhannD and Lennart Hansson, MD, PhD
    • Cleveland Clinic Journal of Medicine May 1992, 59 (3) 248-254;

    • Different beta blockers have different effects on cardiac output and heart rate, and some may diminish detrimental arterial changes induced by hypertension. A long-term preventive effect against coronary artery disease remains to be demonstrated.

  • The hemodynamic effects of adrenergic blocking agents

    Donald G. Vidt, MD, Alan Bakst, PharmD and Per Lund-Johansen
    • Cleveland Clinic Journal of Medicine March 1992, 59 (2) 193-200;

    • Alpha-1 blockers may suit patients with active life-styles, peripheral vascular disorders, or high blood-cholesterol levels, while beta blockers are useful in tachycardia, palpitations, or angina pectoris. An overview of the pharmacologic qualities and numerous clinical applications of these agents.

  • Treating hypertension to prevent coronary disease

    Norman M. Kaplan, MD
    • Cleveland Clinic Journal of Medicine September 1991, 58 (5) 432-443;

    • Past successes and failures in treating hypertension suggest ways to provide better overall therapy and reduce the incidence of coronary heart disease.

  • Alpha- and beta-blocking agents: pharmacology and properties

    Donald G. Vidt, MD, Alan Bakst, PharmD and B.N.C. Prichard
    • Cleveland Clinic Journal of Medicine July 1991, 58 (4) 337-350;

    • Continued investigations into the multiple effects of certain alpha and beta blockers may provide clues to more effective treatment of hypertension.

  • Tailoring antihypertensive therapy in 1991

    Donald G. Vidt, MD and Alan Bakst, PharmD
    • Cleveland Clinic Journal of Medicine May 1991, 58 (3) 277-284;

    • The trend is toward individualized treatment and away from rigid stepped care.

Previous
Next